Sandoz Group AG (Sandoz Group AG) FCF Yield % : -1.74 (As of May. 25, 2024)

View and export this data going back to 2023. Start your Free Trial

What is Sandoz Group AG FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Sandoz Group AG's Trailing 12-Month Free Cash Flow is $-263 Mil, and Market Cap is $15,054 Mil. Therefore, Sandoz Group AG's FCF Yield % for today is -1.74%.

The historical rank and industry rank for Sandoz Group AG's FCF Yield % or its related term are showing as below:

SDZNY' s FCF Yield % Range Over the Past 10 Years
Min: -1.77 Med: 0 Max: 0
Current: -1.74

SDZNY's FCF Yield % is ranked worse than
56.14% of 1083 companies
in the Drug Manufacturers industry
Industry Median: -0.46 vs SDZNY: -1.74

Sandoz Group AG's FCF Margin % for the quarter that ended in Dec. 2023 was -2.64%.

Sandoz Group AG FCF Yield % Historical Data

The historical data trend for Sandoz Group AG's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sandoz Group AG FCF Yield % Chart

Sandoz Group AG Annual Data

Trend

Dec22

Dec23

FCF Yield %

-1.91

Sandoz Group AG Quarterly Data
	Dec22	Dec23
FCF Yield %	-	-7.64

Competitive Comparison of Sandoz Group AG's FCF Yield %

For the Drug Manufacturers - Specialty & Generic subindustry, Sandoz Group AG's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sandoz Group AG's FCF Yield % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sandoz Group AG's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Sandoz Group AG's FCF Yield % falls into.

Sandoz Group AG FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Sandoz Group AG's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	/	Market Cap
	=	-263	/	13762.02729
	=	-1.91%

Sandoz Group AG's annualized FCF Yield % for the quarter that ended in Dec. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	*	Annualized Factor	/	Market Cap
	=	-263	*	4	/	13762.02729
	=	-7.64%

Sandoz Group AG FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

Sandoz Group AG FCF Yield % Related Terms

Thank you for viewing the detailed overview of Sandoz Group AG's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Sandoz Group AG (Sandoz Group AG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sandoz Group AG (OTCPK:SDZNY) » Definitions » FCF Yield %

Comparable Companies

Traded in Other Exchanges

SDZXF:USA SDZz:UK D8Y0:Germany SDZ:Switzerland

Address

Forum 1, Novartis Campus, Basel, CHE, CH-4056

Website

https://www.sandoz.com

Sandoz is one of the largest generic pharmaceutical manufacturers in the world, generating over $9 billion annually from off-patent drugs. Once part of Novartis, Sandoz spun off and went public in October 2023. Generics, including small molecules and complex injectables, make up roughly 75% of Sandoz's total sales, and the firm has a significant presence in Europe, the United States, and other key international markets. Sandoz generates its remaining sales from biosimilars and is among leaders in the space. Sandoz launched Europe's first biosimilar, Omnitrope, in 2006 as well as U.S.'s first biosimilar, Zarxio, in 2015. It currently has eight commercialized biosimilars in a number of markets and has over 20 assets in pipeline.

Sandoz Group AG (Sandoz Group AG) Headlines

From GuruFocus

Q3 2023 Sandoz Group AG Earnings Call Transcript

By GuruFocus Research • 02-14-2024

Q3 2023 Sandoz Group AG Earnings Call Transcript

By GuruFocus Research • 02-14-2024